MannKind Corporation - Common Stock (MNKD)

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload. Chief Executive Officer Michael Castagna said the approval

Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million.

Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index.

This disposition was tied to vesting of performance-based RSUs at 83% of the target.

Tross disposed of 65,808 shares to cover tax withholding from a vested performance award, retaining over 1 million shares in the company.

Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company.

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into children and adolescents. Chief Executive Officer Michael Castagna called the decision “a truly historic

MannKind (MNKD) Q1 2026 Earnings Transcript

MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations.

Mr. Market was hoping for a better fourth quarter than the company delivered.

United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity.

With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left.

The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case.